Singular Begin Period Cash Flow from 2010 to 2024
| OMIC Stock | USD 20.45 0.45 2.25% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 76 M | Current Value 65.2 M | Quarterly Volatility 54.6 M |
Check Singular Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Singular Genomics' main balance sheet or income statement drivers, such as Net Interest Income of 7.7 M, Interest Income of 8.9 M or Depreciation And Amortization of 7.6 M, as well as many indicators such as Price To Sales Ratio of 10.93, Dividend Yield of 0.0 or PTB Ratio of 0.2. Singular financial statements analysis is a perfect complement when working with Singular Genomics Valuation or Volatility modules.
Singular | Begin Period Cash Flow |
Latest Singular Genomics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Singular Genomics Systems over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Singular Genomics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Singular Genomics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Singular Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 24,788,085 | |
| Geometric Mean | 3,581,971 | |
| Coefficient Of Variation | 220.17 | |
| Mean Deviation | 35,811,203 | |
| Median | 1,118,000 | |
| Standard Deviation | 54,576,247 | |
| Sample Variance | 2978.6T | |
| Range | 200.6M | |
| R-Value | 0.57 | |
| Mean Square Error | 2153.9T | |
| R-Squared | 0.33 | |
| Significance | 0.03 | |
| Slope | 6,994,600 | |
| Total Sum of Squares | 41699.9T |
Singular Begin Period Cash Flow History
About Singular Genomics Financial Statements
Singular Genomics stakeholders use historical fundamental indicators, such as Singular Genomics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Singular Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Singular Genomics' assets and liabilities are reflected in the revenues and expenses on Singular Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Singular Genomics Systems. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 76 M | 65.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out the analysis of Singular Genomics Correlation against competitors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.